Researchers have developed a novel PET imaging technique that allows for the simultaneous visualization of tumor progression and cardiac inflammation during cancer therapy. This advancement was presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting and aims to enhance personalized clinical decision-making. Immune checkpoint inhibitor (ICI) therapies, while effective in improving cancer survival rates, can cause serious cardiovascular side effects in some patients, potentially complicating treatment. The study utilized a CCR2-targeted radiotracer, 64Cu-DOTA-ECL1i, to noninvasively assess immune-related cardiac adverse events in a cardio-oncology model involving atherosclerotic mice. Results indicated that while ICI treatment slowed tumor growth, it increased cardiac inflammation, which was mitigated by the addition of itacitinib, a Janus kinase 1 inhibitor. This combination therapy not only improved tumor response but also reduced inflammatory signals in the heart. The findings suggest that CCR2 PET imaging could help clinicians detect cardiovascular complications early, allowing for safer cancer treatment strategies. Further validation through clinical trials is necessary to confirm these results.